Next Article in Journal
Effects of LL-37 on Gingival Fibroblasts: A Role in Periodontal Tissue Remodeling?
Next Article in Special Issue
Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
Previous Article in Journal
Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs
Previous Article in Special Issue
Human T Cell Memory: A Dynamic View
Open AccessReview

Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man

The Jenner Institute, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
*
Author to whom correspondence should be addressed.
Vaccines 2018, 6(3), 43; https://doi.org/10.3390/vaccines6030043
Received: 5 July 2018 / Revised: 16 July 2018 / Accepted: 20 July 2018 / Published: 21 July 2018
(This article belongs to the Special Issue T Cell Memory to Vaccination)
The development of effective vaccines continues to be a key goal for public health bodies, governments, funding bodies and pharmaceutical companies. With new vaccines such as Shingrix targeting Shingles and Bexsero for Meningitis B, licensed in recent years, today’s population can be protected from more infectious diseases than ever before. Despite this, we are yet to license vaccines for some of the deadliest endemic diseases affecting children, such as malaria. In addition, the threat of epidemics caused by emerging pathogens is very real as exemplified by the 2014–2016 Ebola outbreak. Most licensed vaccines provide efficacy through humoral immunity and correlates of protection often quantify neutralising antibody titre. The role of T-cells in vaccine efficacy is less well understood and more complex to quantify. Defining T-cell responses which afford protection also remains a challenge, although more sophisticated assays for assessing cell-mediated immunity with the potential for higher throughput and scalability are now available and warrant review. Here we discuss the benefits of multiparameter cytokine analysis and omics approaches compared with flow cytometric and ELISpot assays. We also review technical challenges unique to clinical trial studies, including assay validation across laboratories and availability of sample type. Measuring T-cell immunogenicity alongside humoral responses provides information on the breadth of immune responses induced by vaccination. Accurately enumerating and phenotyping T-cell immunogenicity to vaccination is key for the determination of immune correlates of protection. However, identifying such T-cell parameters remains challenging without a clear understanding of the immunological mechanisms by which a T-cell-mediated response induces protection. View Full-Text
Keywords: T-cell; memory; vaccine; pre-clinical; clinical trial T-cell; memory; vaccine; pre-clinical; clinical trial
Show Figures

Figure 1

MDPI and ACS Style

Flaxman, A.; Ewer, K.J. Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man. Vaccines 2018, 6, 43.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop